International fund giants sharply increase their holdings of Hengrui Pharmaceuticals Sun Piaoyang personally denounces 316 million overweight new pharmaceutical companies

Texthaon

In the past two days, when the 2020 financial report and the first quarter of 2021 are announced, Hengrui Medicine (600276) has made various moves.

Please poke the interpretation of Hengrui's latest financial report: sina.

In a lot of information, Sina Medicine noticed two of them, which seemed to have an unclear meaning:

1.

According to the first quarterly report of Hengrui Medicine, with the "national team" and Beijing Capital choosing to lighten up Hengrui Medicine, Oppenheimer Fund increased its holdings by 16.

According to the data, Oppenheimer is one of the largest global asset management companies in the United States.

In 2017, Hengrui's annual report showed that Oppenheimer entered Hengrui Medicine for the first time and became the top ten tradable stocks.

In 2018, Oppenheimer reduced its holdings in Hengrui Pharmaceuticals in the first quarter and the second quarter, and successfully missed a wave of decline in the market.

In 2018, the “black swan” of the pharmaceutical industry frequently appeared.

At the beginning of 2019, Hengrui Pharmaceuticals started an 11-month rebound in the market, the stock price doubled, and the Oppenheimer Fund made huge profits.

In 2020, Oppenheimer Fund also perfectly avoided the market decline at the end of the fourth quarter, reducing its holdings of Hengrui by nearly 16 million shares in the second and third quarters, perfectly staggering the downward trend.

The Oppenheimer Fund’s operations on Hengrui Pharmaceuticals in the past 4 years are like an eye open to the sky.

Today, in the first quarter of 2021, Hengrui Pharmaceuticals, which once had a market value of 600 billion yuan, has fallen by 17% overall, with a maximum amplitude of nearly 30%.

On this occasion, Oppenheimer Fund once again increased its position in Hengrui Medicine, which naturally caused a sensation.

However, it is worth mentioning that the Oppenheimer Fund has also stumbled on Dong Ejiao (000423).
After all, this time the Oppenheimer Fund once again bucked the trend and blessed Hengrui Medicine.
Can we continue to write the investment myth? Wait and see.

2.
Sun Piaoyang's new drug company

On April 19, Hengrui Pharmaceuticals issued an announcement that Shanghai Hengrui and Sun Piaoyang will continue to increase their capital in Ruilidi to support their capital needs.
The two will increase their capital by 474 million yuan and 316 million yuan respectively.
Among them, Shanghai Hengrui's 474 million yuan consists of 390 million yuan invested in four new drug technologies and 84 million yuan in monetary funds.

3 new class 1.
1 drugs are expected to complete clinical phase I in 2021,

1 Class 1.
1 new drug is in the IND stage

In July 2020, Ruilidi was jointly established by Shanghai Hengrui with a contribution of 60 million yuan and Sun Piaoyang's personal contribution of 40 million yuan, responsible for the research and development, production, sales and related import and export business of antiviral therapy.
In this regard, Hengrui Pharmaceuticals stated that antiviral drugs are the company's new field of involvement, and this transaction is conducive to the company's enrichment of product lines.

Many investors believe that Hengrui Pharmaceutical's active involvement in new areas will be a new bargaining chip for Hengrui Pharmaceuticals to stimulate the capital market and digest valuation bubbles.
It will not even rule out the possibility of a separate IPO in the future, opening up a new battlefield for the company.

However, some investors expressed concern that Hengrui Pharmaceuticals, as a leader in my country's pharmaceutical industry, still adopts self-construction methods such as the establishment of Ruili Di to expand its scale.
This is completely different from the growth path of many major international pharmaceutical companies relying on mergers and acquisitions to achieve dominance.
.
If it has been relying solely on the self-built model, will it affect its pace of becoming a global pharmaceutical giant?

Reference source: China Fund News "Escaped Maotai! Oppenheimer makes another move: Contrary to the trend to increase holdings of Hengrui Medicine"